Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 4
1(20.0%)
5Total
N/A(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05496296Not ApplicableRecruiting

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

Role: lead

NCT05424354Phase 4Recruiting

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

Role: lead

NCT05046158Not ApplicableCompleted

Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Role: lead

NCT01062191Not ApplicableTerminated

Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl

Role: lead

NCT01062204Not ApplicableCompleted

Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites

Role: lead

All 5 trials loaded